FR3009496B1 - Formes multiparticulaires a liberation prolongee, procede de leurs preparations et compositions les contenant pour le traitement et/ou prevention de la cyctinurie - Google Patents

Formes multiparticulaires a liberation prolongee, procede de leurs preparations et compositions les contenant pour le traitement et/ou prevention de la cyctinurie

Info

Publication number
FR3009496B1
FR3009496B1 FR1301924A FR1301924A FR3009496B1 FR 3009496 B1 FR3009496 B1 FR 3009496B1 FR 1301924 A FR1301924 A FR 1301924A FR 1301924 A FR1301924 A FR 1301924A FR 3009496 B1 FR3009496 B1 FR 3009496B1
Authority
FR
France
Prior art keywords
cyctinuria
multiparticular
prevention
preparation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1301924A
Other languages
English (en)
Other versions
FR3009496A1 (fr
Inventor
Mohamed Skiba
Skiba Malika Lahiani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR1301924A priority Critical patent/FR3009496B1/fr
Publication of FR3009496A1 publication Critical patent/FR3009496A1/fr
Application granted granted Critical
Publication of FR3009496B1 publication Critical patent/FR3009496B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
FR1301924A 2013-08-12 2013-08-12 Formes multiparticulaires a liberation prolongee, procede de leurs preparations et compositions les contenant pour le traitement et/ou prevention de la cyctinurie Active FR3009496B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1301924A FR3009496B1 (fr) 2013-08-12 2013-08-12 Formes multiparticulaires a liberation prolongee, procede de leurs preparations et compositions les contenant pour le traitement et/ou prevention de la cyctinurie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1301924A FR3009496B1 (fr) 2013-08-12 2013-08-12 Formes multiparticulaires a liberation prolongee, procede de leurs preparations et compositions les contenant pour le traitement et/ou prevention de la cyctinurie

Publications (2)

Publication Number Publication Date
FR3009496A1 FR3009496A1 (fr) 2015-02-13
FR3009496B1 true FR3009496B1 (fr) 2016-02-05

Family

ID=49989820

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1301924A Active FR3009496B1 (fr) 2013-08-12 2013-08-12 Formes multiparticulaires a liberation prolongee, procede de leurs preparations et compositions les contenant pour le traitement et/ou prevention de la cyctinurie

Country Status (1)

Country Link
FR (1) FR3009496B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2061394B1 (es) * 1993-02-05 1995-06-16 Robert S A Lab Procedimiento de fabricacion de un granulado de citrato potasico con cesion retardada.
EP1970066A1 (fr) * 2007-03-12 2008-09-17 Medice Arzneimittel Pütter GmbH & Co. KG Composition pharmaceutique destinée au traitement d'une hyperacidification du sang
FR2967578B1 (fr) * 2010-11-18 2012-12-28 Advicenne Pharma Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie

Also Published As

Publication number Publication date
FR3009496A1 (fr) 2015-02-13

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
MA45192A (fr) Traitement d'association
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA50482A (fr) Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
HK1223616A1 (zh) 多環氨基甲酰基吡啶酮化合物和其用於治療 感染的用途
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
HK1223615A1 (zh) 多環氨基甲酰基吡啶酮化合物和其用於治療 感染的用途
MA52906A (fr) Procédé de préparation d'amg 416
MA43574A (fr) Compositions ayant des amplificateurs de perméation pour l'administration de médicaments
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
FR3011467B1 (fr) Composes et compositions comprenant de tels composes pour la prevention ou le traitement des dyslipidemies
ZA201704957B (en) Composition for the treatment of hepatic veno-occlusive disease
FR3029778B1 (fr) Composition cosmetique comprenant des alpha-olefine sulfonates lineaires, des tensioactifs anioniques et des tensioactifs non ioniques et/ou ampho-teres, et procede de traitement cosmetique
FR20C1044I2 (fr) Triazines pour le traitement des infections protozoïques
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA46999A (fr) Oligonucléotides modifiés pour traiter la polykystose rénale
FR2999191B1 (fr) Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
IN2014MN01733A (fr)
FR3015285B1 (fr) Formulation pour le traitement des cheveux
PL3124048T3 (pl) Kompozycja do stosowania doustnego w leczeniu choroby lub dolegliwości związanych z odpływem żołądkowo-przełykowym
WO2014197536A3 (fr) Nouvelles bêta lactames en tant que modulateurs d'absorption du glutamate et leurs procédés d'utilisation
MA42264A (fr) Procédé de préparation d'oltipraz
FR3049599B1 (fr) Procede de preparation de l'hexafluorobutadiene.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 10

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 11